Prothena Corporation PLC
NASDAQ:PRTA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
SSPN Finance Ltd
BSE:539026
|
IN |
|
Yuhuan CNC Machine Tool Co Ltd
SZSE:002903
|
CN |
|
Alpargatas SA
BOVESPA:ALPA4
|
BR |
|
R
|
Rotem Energy Mineral Rem LP
TASE:RTEN
|
IL |
|
Emergent Industrial Solutions Ltd
BSE:506180
|
IN |
|
Noida Toll Bridge Company Ltd
NSE:NOIDATOLL
|
IN |
|
A
|
Amplifon SpA
LSE:0N61
|
IT |
|
ChangYuan Technology Group Ltd
SSE:600525
|
CN |
|
Arshiya Ltd
NSE:ARSHIYA
|
IN |
Prothena Corporation PLC
Depreciation & Amortization
Prothena Corporation PLC
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Prothena Corporation PLC
NASDAQ:PRTA
|
Depreciation & Amortization
$895k
|
CAGR 3-Years
7%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
1%
|
|
|
Alkermes Plc
NASDAQ:ALKS
|
Depreciation & Amortization
$27.2m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-11%
|
|
|
Amarin Corporation PLC
NASDAQ:AMRN
|
Depreciation & Amortization
$3m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
8%
|
CAGR 10-Years
14%
|
|
|
M
|
Mural Oncology PLC
NASDAQ:MURA
|
Depreciation & Amortization
$3.5m
|
CAGR 3-Years
33%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Prothena Corporation PLC
Glance View
Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. The company is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The firm's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The firm's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aβ) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.
See Also
What is Prothena Corporation PLC's Depreciation & Amortization?
Depreciation & Amortization
895k
USD
Based on the financial report for Dec 31, 2025, Prothena Corporation PLC's Depreciation & Amortization amounts to 895k USD.
What is Prothena Corporation PLC's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
1%
Over the last year, the Depreciation & Amortization growth was 0%. The average annual Depreciation & Amortization growth rates for Prothena Corporation PLC have been 7% over the past three years , -10% over the past five years , and 1% over the past ten years .
